JP2021506817A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021506817A5 JP2021506817A5 JP2020532892A JP2020532892A JP2021506817A5 JP 2021506817 A5 JP2021506817 A5 JP 2021506817A5 JP 2020532892 A JP2020532892 A JP 2020532892A JP 2020532892 A JP2020532892 A JP 2020532892A JP 2021506817 A5 JP2021506817 A5 JP 2021506817A5
- Authority
- JP
- Japan
- Prior art keywords
- dose
- day
- treatment cycle
- administered
- cea
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17207423 | 2017-12-14 | ||
| EP17207423.9 | 2017-12-14 | ||
| EP18160044.6 | 2018-03-05 | ||
| EP18160044 | 2018-03-05 | ||
| PCT/EP2018/084652 WO2019115659A1 (en) | 2017-12-14 | 2018-12-13 | Use of a cea cd3 bispecific antibody and a pd-1 axis binding antagonist in a dosage regime to treat cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021506817A JP2021506817A (ja) | 2021-02-22 |
| JP2021506817A5 true JP2021506817A5 (https=) | 2022-01-11 |
Family
ID=64607022
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020532892A Pending JP2021506817A (ja) | 2017-12-14 | 2018-12-13 | がんを治療するための投与計画におけるｃｅａ ｃｄ３二重特異性抗体及びｐｄ−１軸結合アンタゴニストの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20200407450A1 (https=) |
| EP (1) | EP3723799A1 (https=) |
| JP (1) | JP2021506817A (https=) |
| KR (1) | KR20200099135A (https=) |
| CN (1) | CN111212660A (https=) |
| AU (1) | AU2018382966A1 (https=) |
| CA (1) | CA3079039A1 (https=) |
| IL (1) | IL275225A (https=) |
| MX (1) | MX2020006125A (https=) |
| TW (1) | TW201934578A (https=) |
| WO (1) | WO2019115659A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6949030B2 (ja) * | 2016-01-08 | 2021-10-13 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Ｐｄ−１軸結合アンタゴニスト及び抗ｃｅａ／抗ｃｄ３二重特異性抗体を用いたｃｅａ陽性がんの治療方法 |
| CN114786776B (zh) | 2019-09-18 | 2026-03-24 | 拉姆卡普生物阿尔法股份公司 | 针对ceacam5和cd3的双特异性抗体 |
| JP2023530961A (ja) * | 2020-06-19 | 2023-07-20 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ｃｄ３に結合する抗体 |
| CN115916830A (zh) * | 2020-06-25 | 2023-04-04 | 豪夫迈·罗氏有限公司 | 抗cd3/抗cd28双特异性抗原结合分子 |
| KR20260049221A (ko) * | 2023-07-29 | 2026-04-13 | 상하이 카이진 바이오테크놀로지, 리미티드 | 변형된 e형 다중특이성 항체 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| AU675929B2 (en) | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| CN101928344B (zh) | 2002-10-17 | 2014-08-13 | 根马布股份公司 | 抗cd20的人单克隆抗体 |
| EP3263596A1 (en) | 2002-12-16 | 2018-01-03 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| ES2672640T3 (es) | 2003-11-05 | 2018-06-15 | Roche Glycart Ag | Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas |
| WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
| CN107227335A (zh) | 2009-10-27 | 2017-10-03 | 安进研发（慕尼黑）股份有限公司 | 用于施用CD19xCD3双特异性抗体的给药方案 |
| MX375359B (es) * | 2013-02-26 | 2025-03-06 | Roche Glycart Ag | Moléculas biespecíficas de unión a antígeno activadoras de células t. |
| WO2016019969A1 (en) * | 2014-08-08 | 2016-02-11 | Ludwig-Maximilians-Universität München | Subcutaneously administered bispecific antibodies for use in the treatment of cancer |
| RS60739B1 (sr) | 2014-11-17 | 2020-09-30 | Regeneron Pharma | Postupci za lečenje tumora upotrebom cd3xcd20 bispecifičnog antitela |
| DK3221355T3 (da) * | 2014-11-20 | 2020-12-07 | Hoffmann La Roche | Kombinationsbehandling med T-celleaktiverende bispecifikke antigenbindende molekyler CD3 og folatreceptor 1 (FolR1) samt PD-1-aksebindende antagonister |
| EP4026848A1 (en) * | 2015-12-09 | 2022-07-13 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody for reducing the cytokine release syndrome |
| JP6949030B2 (ja) * | 2016-01-08 | 2021-10-13 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Ｐｄ−１軸結合アンタゴニスト及び抗ｃｅａ／抗ｃｄ３二重特異性抗体を用いたｃｅａ陽性がんの治療方法 |
| WO2018093821A1 (en) | 2016-11-15 | 2018-05-24 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
-
2018
- 2018-12-13 CA CA3079039A patent/CA3079039A1/en active Pending
- 2018-12-13 AU AU2018382966A patent/AU2018382966A1/en not_active Abandoned
- 2018-12-13 EP EP18814941.3A patent/EP3723799A1/en not_active Withdrawn
- 2018-12-13 CN CN201880066731.2A patent/CN111212660A/zh active Pending
- 2018-12-13 JP JP2020532892A patent/JP2021506817A/ja active Pending
- 2018-12-13 KR KR1020207015873A patent/KR20200099135A/ko not_active Ceased
- 2018-12-13 WO PCT/EP2018/084652 patent/WO2019115659A1/en not_active Ceased
- 2018-12-13 MX MX2020006125A patent/MX2020006125A/es unknown
- 2018-12-13 TW TW107145062A patent/TW201934578A/zh unknown
-
2020
- 2020-06-08 IL IL275225A patent/IL275225A/en unknown
- 2020-06-10 US US16/898,248 patent/US20200407450A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021506817A5 (https=) | ||
| JP6817492B2 (ja) | 高いインビボ忍容性を有するアントラサイクリン系の抗体薬物複合体 | |
| JP2025138634A (ja) | Ｂ細胞成熟抗原を標的にする多重特異性抗体のための投与計画及び組み合わせ治療 | |
| RU2019134352A (ru) | Новые биспецифические антигенсвязывающие молекулы, обладающие способностью специфически связываться с cd40 и fap | |
| JP2019502676A5 (https=) | ||
| JP2020516240A5 (https=) | ||
| JP2011501656A5 (https=) | ||
| JP2022169589A5 (https=) | ||
| JP2014114288A5 (https=) | ||
| FI3484915T3 (fi) | Uusia zikavirusepitooppeihin spesifisesti sitoutuvia vasta-aineita ja niiden käyttöjä | |
| RU2009110102A (ru) | Лечение опухолей с помощью антитела к vegf | |
| JP2014502955A5 (https=) | ||
| AU2021221287B2 (en) | Engineered anti-IL-2 antibodies | |
| JP2016538318A5 (https=) | ||
| JP2020500834A5 (https=) | ||
| JP2025038088A5 (https=) | ||
| RU2018107693A (ru) | Комбинированные виды лечения и их варианты применения и способы | |
| JP2020502219A5 (https=) | ||
| JP2021531732A5 (https=) | ||
| CN113574069A (zh) | 抗pd-l1抗体及其用途 | |
| JP2020537690A (ja) | プレクチン１結合抗体およびその使用 | |
| JP2020521798A5 (https=) | ||
| JPWO2022256559A5 (https=) | ||
| US9486475B2 (en) | PPS for the prevention of potential adverse effects caused by CD3 specific binding domains | |
| EP4615881A1 (en) | Bispecific antibody compounds |